In the last trading session, 10.83 million Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) shares changed hands as the company’s beta touched 1.17. With the company’s per share price at $0.42 changed hands at -$0.02 or -5.48% during last session, the market valuation stood at $151.43M. LXRX’s last price was a discount, traded about -483.33% off its 52-week high of $2.45. The share price had its 52-week low at $0.28, which suggests the last value was 33.33% up since then. When we look at Lexicon Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 56.55 million shares, with the 3-month average coming to 14.89 million.
Analysts gave the Lexicon Pharmaceuticals Inc (LXRX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.17. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LXRX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Lexicon Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.1.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) trade information
Instantly LXRX was in red as seen at the end of in last trading. With action -26.57%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -43.28%, with the 5-day performance at -26.57% in the red. However, in the 30-day time frame, Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) is 13.92% up. Looking at the short shares, we see there were 39.26 million shares sold at short interest cover period of 4.04 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 93.0% from its current market value. According to analyst projections, LXRX’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -1328.57% plunge from its current level, while the stock would need to soar -1328.57% for it to hit the projected low.
Lexicon Pharmaceuticals Inc (LXRX) estimates and forecasts
Year-over-year growth is forecast to reach -72.33% down from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 1.26M. 4 analysts are of the opinion that Lexicon Pharmaceuticals Inc’s revenue for the current quarter will be 1.33M. The company’s revenue for the corresponding quarters a year ago was 1.13M and 1.65M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 11.73%. The estimates for the next quarter sales put growth at -19.25%.
The 2025 estimates are for Lexicon Pharmaceuticals Inc earnings to increase by 41.27%, but the outlook for the next 5-year period is at 22.79% per year.
LXRX Dividends
Lexicon Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-Mar-05.
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.17% of Lexicon Pharmaceuticals Inc shares while 84.11% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 85.11%. There are 84.11% institutions holding the Lexicon Pharmaceuticals Inc stock share, with ARTAL GROUP S.A. the top institutional holder. As of 2024-06-30, the company held 56.3318% of the shares, roughly 175.1 million LXRX shares worth $294.17 million.
FMR LLC holds the second largest percentage of outstanding shares, with 12.4462% or 38.69 million shares worth $64.99 million as of 2024-06-30.
Among Mutual Funds, the top two as of Feb 28, 2025 were Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund . With 16.86 shares estimated at $7.06 million under it, the former controlled 4.66% of total outstanding shares. On the other hand, Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund held about 1.49% of the shares, roughly 5.4 shares worth around $2.26 million.
